These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 25563769)

  • 1. Bevacizumab for metastatic colon cancer: does patient BMI influence survival?
    Kaidar-Person O; Badarna H; Bar-Sela G
    Anticancer Drugs; 2015 Mar; 26(3):363-6. PubMed ID: 25563769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
    Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
    Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
    Smith I; Pierga JY; Biganzoli L; Cortes-Funes H; Thomssen C; Saracchini S; Nisenbaum B; Pelaez I; Duenne AA; Pritchard KI
    Breast Cancer Res Treat; 2011 Nov; 130(1):133-43. PubMed ID: 21830015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
    Dignam JJ; Polite BN; Yothers G; Raich P; Colangelo L; O'Connell MJ; Wolmark N
    J Natl Cancer Inst; 2006 Nov; 98(22):1647-54. PubMed ID: 17105987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Factors Affecting Bevacizumab Efficacy With and Without Conventional Chemotherapy in Metastatic Colon Cancer.
    Islam R; Khan R; Ali A; Kollu V; Phan T; Chyou PH; Burmester JK; Kibriya MG
    Am J Ther; 2020; 27(5):e500-e506. PubMed ID: 32902937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
    Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
    Innominato PF; Giacchetti S; Moreau T; Bjarnason GA; Smaaland R; Focan C; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Poncet A; Spiegel D; Lévi F;
    Cancer; 2013 Jul; 119(14):2564-73. PubMed ID: 23633399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
    Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
    Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
    Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
    Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
    Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
    Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.